A multi-centre (UK) double-blind randomised parallel group placebo controlled trial to evaluate the efficacy, safety, and tolerability of Intravenous Immunoglobulin (IVIg) 0.5g/kg plus standard treatment, versus matched placebo plus standard treatment in patients with longstanding Complex Regional Pain Syndrome

Trial Profile

A multi-centre (UK) double-blind randomised parallel group placebo controlled trial to evaluate the efficacy, safety, and tolerability of Intravenous Immunoglobulin (IVIg) 0.5g/kg plus standard treatment, versus matched placebo plus standard treatment in patients with longstanding Complex Regional Pain Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Immune globulin (Primary) ; Analgesics
  • Indications Complex regional pain syndromes
  • Focus Therapeutic Use
  • Acronyms LIPS
  • Most Recent Events

    • 01 Dec 2015 Status changed from recruiting to completed, according to ISRCTN: Current Controlled Trials record.
    • 05 Nov 2015 Accrual to date is 102% according to United Kingdom Clinical Research Network .
    • 04 Oct 2015 Accrual to date is 98% according to United Kingdom Clinical Research Network .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top